Proactive Investors - Run By Investors For Investors

Cello Health on track and buoyed by strength of pharma consultancy

The health division saw good like-for-like gross profit growth and better operating margins
pills
Work for big pharma has increased

Cello Health plc (LON:CLL) expects to hit expectations for 2018 after an “excellent year” at its big pharma consultancy division.

Strong like-for-like growth in this arm, known as health, offset a slower outcome from brand and marketing operation Signal.

WATCH: Cello Health Plc expects to hit expectations for 2018 after 'excellent year'

The health division also saw good like-for-like gross profit growth and better-operating margins.

Operating profit performance was good in all three core capabilities consulting, insight and communications, said the statement.

"Contributions from the businesses acquired in 2017 continue to be in line with the board's expectations, extending the reach of Cello Health into the biotech community to complement the pharmaceutical core of the business and increasing the focus on the US market."

Signal’s slower year reflected lower activity by some UK-based clients.

Full year results will include £1.2mln of start-up costs for the launch of social media analytics tool Pulsar in the US and the new Boston office of Cello Health. Restructuring Signal’s capacity in Cheltenham has also cost £300,000.

Pulsar US will be consolidated into the group’s results in 2019.

 

View full CLL profile View Profile

Cello Health PLC Timeline

Video
April 11 2019
Big Picture
March 22 2019

Related Articles

books
May 22 2019
Here we take a closer look at Bloomsbury Publishing PLC (LON:BMY)
mobile marketing
April 02 2019
The merger is structured as an offer by Taptica that will see it owning 50.1% of the enlarged group and Rhythm One owning the remaining 49.9%
Live Company
June 13 2019
In June 2019 the company signed a five-year deal to create tours themed around properties owned by children’s television network Nickelodeon

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use